Cited by 143Thyroid Cancer Diagnosis and TreatmentThyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.

New therapeutic approaches for metastatic thyroid carcinoma

Baudin, Eric, Schlumberger, Martin·2007·The Lancet Oncology

DOI 10.1016/s1470-2045(07)70034-7

Open this paper in CoChat — free account

Abstract

Treatment of metastatic differentiated thyroid cancer (DTC) includes the use of radioiodine and suppressive thyroid hormone treatment. A third of patients with distant metastases (who have radioiodine uptake, are younger than 40 years, have small metastases, and have well differentiated thyroid tumour) can be cured with radioiodine treatment. For other patients, there are no effective treatment modalities. However, the recent availability of molecularly targeted treatments has led to changes in the treatment strategy for DTC in patients with distant metastases, especially in those who are resistant to radioiodine treatment.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(07)70034-7

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Williams Textbook of Endocrinology
Melmed, S., & Polonsky, K. S. (2016) · Elsevier eBooks · doi:10.1016/c2013-0-15980-6 · Cited by 3,715
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,379
International Histological Classification of Tumours
Weller, R. (1981) · Journal of Clinical Pathology · doi:10.1136/jcp.34.6.692-d · Cited by 2,047
Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,014
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
Pacini, F., Schlumberger, M. J., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W. M., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,970
Self-citation
Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy
Durante, C., Haddy, N., Baudin, É., Leboulleux, S., Hartl, D. M., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J., de Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,670
Self-citation
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,402
Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long‐term Outcome in 2444 Consecutively Treated Patients
HAY, I. D., Thompson, G. B., Grant, C. S., Bergstralh, E. J., Dvorak, C. E., Gorman, C. A., Maurer, M. S., McIver, B., Mullan, B. P., Oberg, A. L., et al. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6612-1 · Cited by 731
RAS Point Mutations and PAX8-PPARγ Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma
Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., Alexander, E. K., Dorn, G. W., Tallini, G., Kroll, T. G., & Nikiforov, Y. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021907 · Cited by 711
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin, J. A., MATSUO, K., Karmakar, A., Chen, D. L., Tang, S., & Koeffler, H. P. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116168 · Cited by 647
Histological Typing of Thyroid Tumours
Hedinger, C. E. (1988) · Springer eBooks · doi:10.1007/978-3-642-61383-8 · Cited by 634
Prognostic Factors for Persistent or Recurrent Disease of Papillary Thyroid Carcinoma with Neck Lymph Node Metastases and/or Tumor Extension beyond the Thyroid Capsule at Initial Diagnosis
Leboulleux, S., Rubino, C., Baudin, É., Caillou, B., Hartl, D. M., Bidart, J., Travagli, J., & Schlumberger, M. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0285 · Cited by 585
Self-citation
Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning
Robbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gönen, M., Strausś, H. W., Tuttle, R. M., Drucker, W. D., & Larson, S. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1534 · Cited by 582
Pattern of Nodal Metastasis for Primary and Reoperative Thyroid Cancer
Machens, A., Hinze, R., Thomusch, O., & Dralle, H. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0176-3 · Cited by 507
BAY 43-9006 Inhibition of Oncogenic RET Mutants
Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. M. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 475
Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation
Knauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X.-H., Refetoff, S., Nikiforov, Y. E., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0047 · Cited by 414
Radioiodsne-131 In the Diagnosis and Treatment of Metastatic Weil Differentiated Thyroid Cancer
Maxon, H. R., & Smith, H. S. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30317-7 · Cited by 409
Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological Features
Bunone, G., Vigneri, P. G., Mariani, L., Butó, S., Collini, P., Pilotti, S., Pierotti, M. A., & Bongarzone, I. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65515-0 · Cited by 395
Survival and Therapeutic Modalities in Patients with Bone Metastases of Differentiated Thyroid Carcinomas
Bernier, M., Leenhardt, L., Hoang, C., Aurengo, A., Mary, J., Ménégaux, F., Enkaoua, E., Turpin, G., Jacques Chiras, C., Saillant, G., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7390 · Cited by 295
Survival and Death Causes in Differentiated Thyroid Carcinoma
Eustatia‐Rutten, C. F. A., Corssmit, E. P. M., Biermasz, N. R., Pereira, A. M., Romijn, J. A., & Smit, J. W. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1322 · Cited by 287
AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts
Polverino, A. J., Coxon, A., Starnes, C. O., Diaz, Z., DeMelfi, T. M., Wang, L., BREADY, J. V., Estrada, J., Cattley, R. C., Kaufman, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4665 · Cited by 286
An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases
Kim, D. W., Jo, Y. S., Jung, H. S., Chung, H. K., Song, J. H., Park, K. C., Park, S. H., Hwang, J. H., Rha, S. Y., Kweon, G. R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2845 · Cited by 279
Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades
Dinneen, S. F., Välimäki, M. J., Bergstralh, E. J., Goellner, J. R., Gorman, C. A., & HAY, I. D. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.7.7608252 · Cited by 273
Immediate Causes of Death in Thyroid Carcinoma: Clinicopathological Analysis of 161 Fatal Cases
Kitamura, Y., Shimizu, K., Nagahama, M., Sugino, K., Ozaki, O., Mimura, T., Ito, K., Ito, K., & Tanaka, S. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.11.6115 · Cited by 271
Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism
Filetti, S., Bidart, J., Arturi, F., Caillou, B., Russo, D., & Schlumberger, M. J. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410443 · Cited by 268
Self-citation
Textbook of Endocrine Surgery
Clark, O. H., Duh, Q., Kebebew, E., Gosnell, J. E., & Shen, W. T. (2016) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/12798 · Cited by 266
Radioisotope concentrator gene therapy using the sodium/iodide symporter gene.
Mandell, R. B., Mandell, L. Z., & Link, C. J. (1999) · PubMed · Cited by 253
Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy.
Boland, A., Ricard, M., Opolon, P., Bidart, J., Yeh, P., Filetti, S., Schlumberger, M. J., & Perricaudet, M. (2000) · PubMed · Cited by 232
Self-citation
Thyroid-hormone therapy and thyroid cancer: a reassessment
Biondi, B., Filetti, S., & Schlumberger, M. J. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0020 · Cited by 222
Self-citation
Restoration of Iodide Uptake in Dedifferentiated Thyroid Carcinoma: Relationship to Human Na+/I- Symporter Gene Methylation Status
Venkataraman, G. M., Yatin, M., Marcinek, R., & Ain, K. B. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5815 · Cited by 222
Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables.
Casara, D., Rubello, D., Saladini, G., Masarotto, G., Favero, A., Girelli, M. E., & Busnardo, B. (1993) · PubMed · Cited by 212
Variation in the clinical courses of adult T-cell leukemia
Kawano, F., Yamaguchi, K., Nishimura, H., Tsuda, H., & Takatsuki, K. (1985) · Cancer · doi:10.1002/1097-0142(19850215)55:4 · Cited by 206
Self-citation
Gene Methylation in Thyroid Tumorigenesis
Xing, M. (2006) · Endocrinology · doi:10.1210/en.2006-0927 · Cited by 176
Incidence of thyroid cancer in adults recorded by French cancer registries (1978–1997)
Colonna, M., Grosclaude, P., Remontet, L., Schvartz, C., Macé-Lesec'h, J., Velten, M., Guizard, A., Trétarre, B., Buémi, A., Arveux, P., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00110-7 · Cited by 175
Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine
Pacini, F., Cetani, F., Miccoli, P., Mancusi, F., Ceccarelli, C., Lippi, F., Martino, E., & Pinchera, A. (1994) · World Journal of Surgery · doi:10.1007/bf00353775 · Cited by 172
Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer
Schiff, B. A., McMurphy, A. B., Jasser, S. A., Younes, M. N., Doan, D., Yigitbasi, O. G., Kim, S., Zhou, G., Mandal, M., Bekele, B. N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0690 · Cited by 168
Low Concentrations of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Increase Expression of the Na+/I- Symporter and Iodine Accumulation in Poorly Differentiated Thyroid Carcinoma Cells
Kitazono, M., Robey, R. W., Zhan, Z., Sarlis, N. J., Skarulis, M. C., Aikou, T., Bates, S. E., & Fojo, T. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7621 · Cited by 163
Iodide Uptake and Experimental 131I Therapy in Transplanted Undifferentiated Thyroid Cancer Cells Expressing the Na+/I- Symporter Gene
Shimura, H., Haraguchi, K., Miyazaki, A., Endo, T., & Onaya, T. (1997) · Endocrinology · doi:10.1210/endo.138.10.5571 · Cited by 159
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy
Fagin, J. A. (2004) · Journal of Endocrinology · doi:10.1677/joe.1.05895 · Cited by 154
Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer
Lennard, C. M., Patel, A. D., Wilson, J., Reinhardt, B. J., Tuman, C., Fenton, C., Blair, E., Francis, G. L., & Tuttle, R. M. (2001) · Surgery · doi:10.1067/msy.2001.112592 · Cited by 148
Combination of Radioiodine (131I) and Probe-Guided Surgery for Persistent or Recurrent Thyroid Carcinoma
Travagli, J. P., Cailleux, A.-F., Ricard, M., Baudin, É., Caillou, B., Parmentier, C., & Schlumberger, M. J. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5014 · Cited by 144
Self-citation
Inhibitors of Raf Kinase Activity Block Growth of Thyroid Cancer Cells with RET/PTC or BRAF Mutations In vitro and In vivo
Ouyang, B., Knauf, J. A., Smith, E. P., Zhang, L., Ramsey, T., Yusuff, N., Batt, D. B., & Fagin, J. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1729 · Cited by 139
ZD6474 Suppresses Oncogenic RET Isoforms in a Drosophila Model for Type 2 Multiple Endocrine Neoplasia Syndromes and Papillary Thyroid Carcinoma
Vidal, M., Wells, S. A., Ryan, A. J., & Cagan, R. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4561 · Cited by 139
Interferon-α-Related Thyroid Disease: Pathophysiological, Epidemiological, and Clinical Aspects
Carella, C., Mazziotti, G., Amato, G., Braverman, L., & Roti, E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0627 · Cited by 132
Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial.
Williams, S. D., Birch, R., & Einhorn, L. H. (1986) · PubMed · Cited by 126
Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?
Grüning, T., Tiepolt, C., Zöphel, K., Bredow, J., Kropp, J., & Franke, W. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480395 · Cited by 125
Restoration of Iodide Uptake in Dedifferentiated Thyroid Carcinoma: Relationship to Human Na+/I- Symporter Gene Methylation Status
Venkataraman, G. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.7.2449 · Cited by 119
Prognostic Factors Associated with the Survival of Patients Developing Loco-Regional Recurrences of Differentiated Thyroid Carcinomas
Rouxel, A., Hejblum, G., Bernier, M., Boëlle, P., Ménégaux, F., Mansour, G., Hoang, C., Aurengo, A., & Leenhardt, L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032004 · Cited by 116
Retinoic Acid and Retinoid X Receptors Are Differentially Expressed in Thyroid Cancer and Thyroid Carcinoma Cell Lines and Predict Response to Treatment with Retinoids
Haugen, B. R., Larson, L. L., Pugazhenthi, U., Hays, W. R., Klopper, J. P., Kramer, C. A., & Sharma, V. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030770 · Cited by 113
Chemotherapy in Metastatic Nonanaplastic Thyroid Cancer: Experience at the Institut Gustave-Roussy
Droz, J., Schlumberger, M. J., Rougier, P. R., Ghosn, M., Gardet, P., & Parmentier, C. (1990) · Tumori Journal · doi:10.1177/030089169007600513 · Cited by 110
Self-citation
Silencing of the Tumor Suppressor GeneSLC5A8Is Associated withBRAFMutations in Classical Papillary Thyroid Carcinomas
Porra, V., Ferraro‐Peyret, C., Durand, C., Selmi‐Ruby, S., Giroud, H., Berger-Dutrieux, N., Decaussin‐Petrucci, M., Peix, J., Bournaud, C., Orgiazzi, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1394 · Cited by 104
Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivo
Luong, Q. T., O’Kelly, J., Braunstein, G. D., Hershman, J. M., & Koeffler, H. P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0367 · Cited by 98
Preventable reoperations for persistent and recurrent papillary thyroid carcinoma
Kouvaraki, M. A., Lee, J. E., Shapiro, S. E., Sherman, S. I., & Evans, D. B. (2004) · Surgery · doi:10.1016/j.surg.2004.06.045 · Cited by 98
AKT in Thyroid Tumorigenesis and Progression
Shinohara, M., Chung, Y. J., Saji, M., & Ringel, M. D. (2006) · Endocrinology · doi:10.1210/en.2006-0937 · Cited by 97
Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer
Braga‐Basaria, M., & Ringel, M. D. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021863 · Cited by 94
Textbook of Endocrine Surgery
(2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0139-7.x5001-7 · Cited by 94
Cytotoxic Effects of Carboplatinum and Epirubicin in the Setting of an Elevated Serum Thyrotropin for Advanced Poorly Differentiated Thyroid Cancer
Santini, F., Bottici, V., Elisei, R., Montanelli, L., Mazzeo, S., Basolo, F., Pinchera, A., & Pacini, F. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011151 · Cited by 91
Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour
de la Torre, N. G., BULEY, I. D., Wass, J. A. H., & Turner, H. E. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01210 · Cited by 89
Effects of Histone Acetylation on Sodium Iodide Symporter Promoter and Expression of Thyroid-Specific Transcription Factors
Puppin, C., D’Aurizio, F., D'Elia, A. V., Cesaratto, L., Tell, G., Russo, D., Filetti, S., Ferretti, E., Tosi, E., Mattei, T., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0128 · Cited by 88
Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer
Santoro, M., & Carlomagno, F. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0073 · Cited by 81
Effects of PTK787/ZK222584, a Tyrosine Kinase Inhibitor, on the Growth of a Poorly Differentiated Thyroid Carcinoma: An Animal Study
Schoenberger, J., Grimm, D. G., Kossmehl, P. P., Infanger, M., Kurth, E., & Eilles, C. (2003) · Endocrinology · doi:10.1210/en.2003-1228 · Cited by 81
Epidermal Growth Factor Receptor as a Therapeutic Target in Human Thyroid Carcinoma: Mutational and Functional Analysis
Mitsiades, C. S., Kotoula, V., Poulaki, V., Sozopoulos, E., Negri, J. M., Charalambous, E., Fanourakis, G., Voutsinas, G. E., Tseleni‐Balafouta, S., & Mitsiades, N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0055 · Cited by 62
Radiation Combined With Antiangiogenic and Antivascular Agents
OʼReilly, M. (2005) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2005.08.006 · Cited by 62
Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma
Mrózek, E., Kloos, R. T., Ringel, M. D., Kresty, L. A., Snider, P., Arbogast, D., Kies, M. S., Munden, R. F., Busaidy, N. L., Klein, M. J., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2498 · Cited by 54
Gene Therapy for Thyroid Cancer: Current Status and Future Prospects
Spitzweg, C., & Morris, J. C. (2004) · Thyroid · doi:10.1089/105072504323150732 · Cited by 52
Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs
Teunissen, J. J. M., Kwekkeboom, D. J., & Krenning, E. P. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.11.005 · Cited by 42
Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers
Schott, M. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01133 · Cited by 39
Inhibition of Metabolic Activity in Papillary Thyroid Carcinoma by a Somatostatin Analogue
Robbins, R. J., Hill, R. H., Wang, W., Macapinlac, H. A., & Larson, S. M. (2000) · Thyroid · doi:10.1089/thy.2000.10.177 · Cited by 35
Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer
Younes, M. N., Yazici, Y. D., Kim, S., Jasser, S. A., El‐Naggar, A. K., & Myers, J. N. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0793 · Cited by 35
Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43–9006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study
Kloos, R. T., Ringel, M. D., Knopp, M. V., Heverhagen, J. T., Rittenberry, J., Weldy, L., Arbogast, D., Collamore, M., King, M., Young, D. C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.5534 · Cited by 30
Surgical Management of Advanced Thyroid Cancer Invading the Aerodigestive Tract
Dralle, H. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0139-7.50038-7 · Cited by 20
Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): A subset analysis from a phase 1 dose-finding study
Boughton, D., Rosen, L. S., Vugt, A. V., Kurzrock, R., Eschenberg, M. J., Wiezorek, J. S., Ingram, M., Wang, D., Stepan, D. E., & Herbst, R. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3030 · Cited by 18
Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathways
Bounacer, A., McGregor, A., Skinner, J. W., BOND, J. A., Poghosyan, Z., & Wynford‐Thomas, D. (2004) · Oncogene · doi:10.1038/sj.onc.1208085 · Cited by 17
A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer
Kim, S., Rosen, L. S., Cohen, E. E. W., Cohen, R. B., Forastiere, A. A., Silva, A. M., Liau, K., ARCHER, R. L., Bycott, P. W., & Vokes, E. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.5529 · Cited by 17
Urine cytology in the detection of renal adenocarcinoma
Piscioli, F., Pusiol, T., Scappini, P., & Luciani, L. (1985) · Cancer · doi:10.1002/1097-0142(19851101)56:9 · Cited by 10

Research works printed but not linked: 1

Brierley, 2006, Bortezomib in patients with metastatic differentiated thyroid cancer: preliminary results of a multicenter phase II study. American Thyroid Association meeting, Phoenix, October 2006, Thyroid, 16, 857

Sorted by citations

Guidelines for radioiodine therapy of differentiated thyroid cancer
Luster, M., Clarke, S. E., Dietlein, M., Laßmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0883-1 · Cited by 725
“Another explanation for the low response rates may be that studies till now have not screened patients for retinoid receptor expression; use of such screening might increase response rates even as it narrows the treated population [ 10 , 100].”
BackgroundInfluential
Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
Carr, L. L., Mankoff, D. A., Goulart, B., Eaton, K. D., Capell, P. T., Kell, E., Bauman, J. E., & Martins, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0994 · Cited by 425
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Sideras, K., Morris, J. C., McIver, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70203-5 · Cited by 420
Thyroid carcinoma: molecular pathways and therapeutic targets
Nikiforov, Y. E. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.10 · Cited by 394
“Preliminary results of the trial in patients with progressive papillary carcinoma have shown minimal or partial response in some patients”
Result
Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis
Nikiforova, M. N., & Nikiforov, Y. E. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.1.83 · Cited by 277

See all 143

Authors: Baudin, E., & Schlumberger, M.
Affiliations: Institut Gustave Roussy (FR)
ORCID: Schlumberger, Martin
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2007-02
Volume: 8
Issue: 2
Pages: 148-156
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(07)70034-7
OpenAlex: W2132185197
Cited by: 143
References: 77
Citations by year: 2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 6 · 2020: 6 · 2019: 1 · 2018: 9 · 2017: 4 · 2016: 11 · 2015: 13 · 2014: 11 · 2013: 7 · 2012: 8
FWCI: 2.30
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
Keywords: metastatic thyroid cancer, differentiated thyroid cancer, radioiodine therapy, targeted therapy, radioiodine resistance, distant metastasis, treatment options
MeSH terms: Humans, Iodine Radioisotopes, Thyroid Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

New therapeutic approaches for metastatic thyroid carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks